A versatile modular vector system for rapid combinatorial mammalian genetics

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1603-1619

  Albers, Joachim ^a   Danzer, Claudia ^a   Rechsteiner, Markus ^b   Lehmann, Holger ^a   Brandt, Laura P ^a   Hejhal, Tomas ^a   Catalano, Antonella ^a   Busenhart, Philipp ^a   Gonçalves, Ana Filipa ^a   Brandt, Simone ^b   Bode, Peter K ^b   Bode Lesniewska, Beata ^b   Wild, Peter J ^b   Frew, Ian J ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P19; PROTEIN P53; TRANSFORMATION RELATED PROTEIN 53; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; CASP9 PROTEIN, HUMAN; CASPASE 9; DOXYCYCLINE; HIF1A PROTEIN, MOUSE; PTEN PROTEIN, HUMAN; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; CRISPR CAS SYSTEM; GENE DELETION; GENE INACTIVATION; GENE INTERACTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ENGINEERING; GENETIC SCREENING; MAMMALIAN GENETICS; MOUSE; MULTIPLE LENTIVIRAL EXPRESSION SYSTEM; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CULTURE; DRUG RESISTANCE; DRUG SCREENING; GENE VECTOR; GENETIC RECOMBINATION; GENETIC TRANSDUCTION; GENETICS; HUMAN; LENTIVIRINAE; MOLECULAR CLONING; PHYSIOLOGY; PROCEDURES; SARCOMA, EXPERIMENTAL; SCID MOUSE;

ANIMALS; APOPTOSIS; CASPASE 9; CELLS, CULTURED; CLONING, MOLECULAR; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DOXYCYCLINE; DRUG RESISTANCE; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LENTIVIRUS; MICE; MICE, SCID; PTEN PHOSPHOHYDROLASE; RECOMBINATION, GENETIC; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING; SARCOMA, EXPERIMENTAL; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926340995     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79743     Document Type: Article

References (60)

1. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127-1133.
2. Lawrence MS, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495-501.
3. Dow LE, Lowe SW. Life in the fast lane: mammalian disease models in the genomics era. Cell. 2012;148(6):1099-1109.
4. Katzen F. Gateway recombinational cloning: a biological operating system. Expert Opin Drug Discov. 2007;2(4):571-589.
5. Paddison PJ, et al. Cloning of short hairpin RNAs for gene knockdown in mammalian cells. Nat Methods. 2004;1(2):163-167.
6. Campeau E, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One. 2009;4(8):e6529.
7. Tsai SQ, et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol. 2014;32(6):569-576.
8. Schambach A, et al. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research. Exp Hematol. 2006;34(5):588-592.
9. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev. 2006;20(2):236-252.
10. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9(10):701-713.
11. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene. 1999;18(19):2967-2987.
12. Filonov GS, Krumholz A, Xia J, Yao J, Wang LV, Verkhusha VV. Deep-tissue photoacoustic tomography of a genetically encoded near-infrared fluorescent probe. Angew Chem Int Ed Engl. 2012;51(6):1448-1451.
13. Filonov GS, Piatkevich KD, Ting L, Zhang J, Kim K, Verkhusha VV. Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat Biotechnol. 2011;29(8):757-761.
14. Hock AK, Lee P, Maddocks OD, Mason SM, Blyth K, Vousden KH. iRFP is a sensitive marker for cell number and tumor growth in high-throughput systems. Cell Cycle. 2013;13(2):1-7.
15. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-1278.
16. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014;32(4):347-355.
17. Sanchez-Rivera FJ, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014;516(7531):428-431.
18. Xue W, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514(7522):380-384.
19. Maddalo D, et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/ Cas9 system. Nature. 2014;516(7531):423-427.
20. Platt RJ, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159(2):440-455.
21. Malina A, et al. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev. 2013;27(23):2602-2614.
22. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. One-step generation of mice carrying reporter and conditional alleles by CRISPR/ Cas-mediated genome engineering. Cell. 2013;154(6):1370-1379.
23. Heckl D, et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol. 2014;32(9):941-946.
24. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev. 2010;24(22):2463-2479.
25. Friedmann-Morvinski D, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science. 2012;338(6110):1080-1084.
26. Madisen L, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci. 2010;13(1):133-140.
27. Tsumura H, Yoshida T, Saito H, Imanaka-Yoshida K, Suzuki N. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene. 2006;25(59):7673-7679.
28. Rubin BP, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011;19(2):177-191.
29. Hettmer S, et al. Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proc Natl Acad Sci U S A. 2011;108(50):20002-20007.
30. Blum JM, et al. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep. 2013;5(4):933-940.
31. Chen X, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013;24(6):710-724.
32. Martinelli S, et al. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer. 2009;48(11):975-982.
33. Paulson V, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011;50(6):397-408.
34. Shern JF, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4(2):216-231.
35. Shukla N, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18(3):748-757.
36. Iolascon A, et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer. 1996;15(4):217-222.
37. Kohashi K, et al. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol. 2008;134(10):1097-1103.
38. Perot G, et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol. 2010;177(4):2080-2090.
39. McIntyre GJ, et al. Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success. Virol J. 2009;6:184.
40. An W, Telesnitsky A. Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells. Virology. 2001;286(2):475-482.
41. ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006;14(6):883-892.
42. ter Brake O, t Hooft K, Liu YP, Centlivre M, von Eije KJ, Berkhout B. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther. 2008;16(3):557-564.
43. Biffi A, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158.
44. Aiuti A, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341(6148):1233151.
45. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther. 2001;12(15):1893-1905.
46. Kohsaka S, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46(6):595-600.
47. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013;10(10):977-979.
48. Siwko SK, et al. Lentivirus-mediated oncogene introduction into mammary cells in vivo induces tumors. Neoplasia. 2008;10(7):653-662.
49. Xia Y, et al. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol. 2012;14(3):257-265.
50. Zufferey R, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873-9880.
51. Dull T, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-8471.
52. Hwang WY, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013;31(3):227-229.
53. Albers J, et al. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med. 2013;5(6):949-964.
54. Grant KS, Wira CR. Effect of mouse uterine stromal cells on epithelial cell transepithelial resistance (TER) and TNFa and TGFβ release in culture. Biol Reprod. 2003;69(3):1091-1098.
55. Romanowska M, Haritonova N, Foerster J. Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med. 2007;9(7):579-584.
56. Tonini T, Claudio PP, Giordano A, Romano G. Determination of functional viral titer by drugresistance colony assay, expression of green fluorescent protein, and beta-galactoside staining. Methods Mol Biol. 2004;285:149-153.
57. Frew IJ, et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J. 2008;27(12):1747-1757.
58. Groszer M, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science. 2001;294(5549):2186-2189.
59. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A. 2007;104(7):2301-2306.
60. Ryan HE, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 2000;60(15):4010-4015.